drugset / Trial / NCT02209324
Open-label Study of ASP2151 in Herpes Simplex Patients
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, open-label study is conducted to evaluate the efficacy and safety of ASP2151 in patients with herpes simplex (recurrent labial/facial herpes and recurrent genital herpes and Kaposi varicelliform).
Timeline
- Start
- 2013-11
- Primary completion
- 2015-07
- Completion
- 2015-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amenamevir | Small molecule | 200 mg | — |